Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0LUWVA
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
HuIgG1-29
|
|||||
| Synonyms |
HuIgG1 29
Click to Show/Hide
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 1 Indication(s)
Investigative
|
|||||
| Antibody Name |
Undisclosed
|
|||||
| Antigen Name |
Epidermal growth factor receptor (EGFR); Receptor tyrosine-protein kinase erbB-3 (ERBB3)
|
Antigen Info | ||||
| Payload Name |
PNU-159682
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase 2-alpha (TOP2A)
|
Target Info | ||||
| Linker Name |
PNU-thiazole cleavable linker 29
|
Linker Info | ||||
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) | 1.40 nM | Positive CD46 expression (CD46 +++/++) | ||
| Method Description |
Cells were seeded at 5000 per well in a 96-well plate in complete RPMI 1640. Antibody-ZAP complexes (Advanced Targeting Systems; produced according to manufacturer's instructions) or ADCs were added to the cells and plates incubated for 72 hours and 5% carbon dioxide.
|
||||
| In Vitro Model | Uterine sarcoma | MES-SA cells | CVCL_1404 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) | 2.00 nM | Positive CD46 expression (CD46 +++/++) | ||
| Method Description |
Cells were seeded at 5000 per well in a 96-well plate in complete RPMI 1640. Antibody-ZAP complexes (Advanced Targeting Systems; produced according to manufacturer's instructions) or ADCs were added to the cells and plates incubated for 72 hours and 5% carbon dioxide.
|
||||
| In Vitro Model | Normal | HEK293T cells | CVCL_0063 | ||
References
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.
